"This isn't about you," Rep. Alexandria Ocasio-Cortez (D-NY) told Gilead CEO Daniel O'Day. "We have legislated a system that allows [this] to happen."
Activists say this relatively small giveaway won't advance PrEP access or help end HIV in the U.S. the way a true price reduction would.
Activists and doctors say they're ready to go further if Gilead won't agree to -- or the U.S. government won't force -- a price reduction to make PrEP accessible to more Americans who need it.
The #PrEP4All campaign made the call for affordable pre-exposure prophylaxis a national news story.
But a survey reveals that about a third of black and Latino gay men would be willing to pay more than $50 per month for a prescription.
In a debate during a plenary session, Michael Saag, M.D., argued for more activism to make PrEP accessible to people who need it.
Introduction AIDS Vaccines
The Thai Trial: A Shot in the Arm Other Vaccines Why Has AIDS Vaccine Research Been so Challenging? What's Next?
Can a Pill a Day Prevent HIV?
Hope in 2010 Rectal Microbicides